New Website Provides Essential Information
on Company's Strategic Initiative
TORONTO, Feb. 18, 2021 /CNW/ - SQI Diagnostics Inc. (the
"Company" or "SQI") (TSX-V: SQD) (OTCQB: SQIDF), a precision
medicine company that discovers, develops, and commercializes
innovative rapid diagnostic testing for healthcare professionals,
patients and consumers worldwide, today is proud to announce the
launch of its newly redesigned website at
https://www.sqidiagnostics.com. The revamped site features a
streamlined, modern design, improved functionality and easy access
to essential information to help educate all stakeholders about the
Company and its new strategic vision, including the latest product
development and investor information.
![SQI Diagnostics Inc. (CNW Group/SQI Diagnostics Inc.) SQI Diagnostics Inc. (CNW Group/SQI Diagnostics Inc.)](https://mma.prnewswire.com/media/1439844/SQI_Diagnostics_Inc__SQI_Diagnostics_Announces_New_Corporate_Web.jpg)
"We are thrilled to debut our new Company website to our
customers, partners, investors and visitors who are looking to
understand the breadth of SQI's products and services," said
Rob Chioini, SQI's CEO. "This new
comprehensive website redesign truly encompasses our Company vision
and enables each visitor to have the same experience and access to
our new product development for our novel COVID-19 and lung
transplantation diagnostics, along with our home testing platform
and custom pharmaceutical diagnostic services."
About SQI Diagnostics
SQI Diagnostics, Inc. is a precision medicine company that
discovers, develops, and commercializes innovative rapid diagnostic
testing for healthcare providers, patients, and consumers
worldwide. The Company's proprietary advanced diagnostics target
organ transplant, autoimmune disease and COVID-19 testing which
includes the developmental direct-to-consumer COVID-19 HOME
Antibody Test, the RALI-Dx™ COVID-19 Severity Triage
Test and the COVID-19 RALI-fast™ Severity Triage
Point-of-Care (POC) Test. SQI's rapid diagnostic tests are intended
to be sold to healthcare professionals so that patients can get
accurate results and fast effective treatment, and
direct-to-consumers so that individuals can be empowered to improve
their health outcomes from the comfort of home.
SQI is fast-tracking the development of three COVID-19
diagnostic tests: a direct-to-consumer COVID-19 Antibody Test and
two COVID-19 Severity Triage tests. The COVID-19 HOME Antibody Test
identifies the presence of IgM, IgA and IgG antibodies of
SARS-CoV-2 in individuals suspected to have been infected with
COVID-19 and asymptomatic individuals wanting to know if they have
been exposed. The test is > 99% accurate with results delivered
in 24-48 hours. The Company currently expects to apply to the U.S.
Food and Drug Administration ("FDA") for Emergency Use
Authorization ("EUA") for its COVID-19 HOME Antibody Test in the
second quarter of calendar year 2021. Should the COVID-19 HOME
Antibody Test receive regulatory approval, the test is expected to
be available direct-to-consumer which would allow individuals to
avoid travelling to a clinic or hospital to be tested for the
presence of the SARS-CoV-2 antibody.
The RALI-Dx™ COVID-19 Severity Triage Test and the
RALI-fast™ COVID-19 Severity Triage POC Test each
help clinicians identify which patients with SARS-CoV-2 will have a
severe inflammatory response and should be admitted to the hospital
or not. Both tests measure the critical biomarker IL-6 which plays
a key role in the cytokine storm phase of COVID-19. The RALI-Dx™
delivers results from the lab in about 50 minutes while the
RALI-fast™ delivers results at the patient
point-of-care in about 15 minutes. The Company currently expects to
apply for EUA to the FDA and for an Interim Order with Health
Canada for both tests in the first and second quarters of calendar
year 2021, respectively.
Under organ transplant, SQI is pioneering the development of an
advanced diagnostic test that increases the chance of successful
lung transplant by assessing the health of the donor organ prior to
transplant surgery. The Company's developmental
TORdx™ Lung Test can detect inflammation at the
molecular level to assess the health of the donor lung, enabling
surgeons to transplant healthy lungs which otherwise would have
been rejected; there is currently no other such test. SQI has
partnered clinical development with the University Health Network
(UHN) Hospitals, one of the largest health and medical research
organizations in North America.
Upon regulatory approval of the TORdx™ Lung Test,
clinical development is planned for diagnostic tests designed to
increase the chance of successful kidney and liver transplant.
Under autoimmune disease testing, SQI has a direct-to-consumer
Celiac Disease and a Rheumatoid Arthritis (RA) Test that enable
people to screen for the diseases from the comfort of their home.
The direct-to-consumer RA Test can help identify and confirm RA
symptoms for timely care and treatment. The direct-to-consumer
Celiac Test confirms disease and validates the effectiveness of
dietary and lifestyle changes to confirm the autoimmune response is
improving.
The Company is not making any express or implied claims that its
products can eliminate, cure or contain COVID-19 (or SARS-2
Coronavirus) at this time. For its research and development, the
Company is collaborating with UHN Hospitals, one of the largest
health and medical research organizations in North
America.
For more information, please visit
www.sqidiagnostics.com.
FORWARD-LOOKING INFORMATION
This press release contains certain words and
statements, which may constitute "forward-looking statements"
within the meaning of applicable securities
laws. Such forward-looking statements may be
identified by words such as "anticipates", "plans", "proposes",
"estimates", "intends", "expects", "believes", "may" and "will".
The forward-looking statements reflect the current
views of the Company with respect to future events and are subject
to certain risks and uncertainties detailed in the Company's
ongoing filings with the securities regulatory authorities,
available to the public at www.sedar.com. Such statements are
subject to numerous important factors, risks and uncertainties,
many of which are beyond the company's control, that may cause
actual events or results to differ materially from the company's
current expectations. Management's expectations and therefore any
forward-looking statements in this press release could be affected
by risks and uncertainties relating to a number of factors,
including, but not limited to, the following: the development and
viability the Company's COVID-19 HOME Antibody Test,
its COVID-19 RALI-dx™ Severity Triage Test and its
COVID-19 RALI-fast™ Severity Triage Point-of-Care (POC)
Test, the suitability of such tests for advanced clinical testing,
including human trials, the content and timing of
decisions made by the FDA relating to the use and commercialization
of such tests, the timing and costs involved in establishing
the commercialization of the tests, the impact that the ongoing
COVID-19 pandemic may have on the company's business, including the
expected development, manufacturing, regulatory and
commercialization timelines relating to the aforementioned
COVID-19-related tests. Readers are cautioned not to place undue
reliance on these forward-looking statements. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements either as a result of new information,
future events or otherwise, except as required by applicable
securities laws
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sqi-diagnostics-announces-new-corporate-website-301231301.html
SOURCE SQI Diagnostics Inc.